Consumers of personal care and cosmetic products have been protected for many years by regulatory organizations, always providing the most advanced science in order to ensure a better safety evaluation of products and ingredients. Since the middle of the 20th century, ethical considerations have been emerging concerning animal experimentation. The cosmetic industry was the first to have restrictions on animal experimentation. Bans were implemented for animal experimentation with regard to ingredients and finished product evaluation in Europe in 2013. As a result, a lot of recent changeovers have been observed in the field of toxicology and in the consideration of alternative methods. This article aims to sum up the evolution of ethical considerations and the establishment of specific regulations worldwide, focusing on alternative methods. At the present day, and as the third market leader of cosmetics at this time, and considering its promising future, a special attention will be given to Brazil.
Introduction
T he use of animals in life sciences comes from medical experiments performed in ancient Greece. However, today, the consciousness of animal testing from a psychological and a cognitive point of view and the need for more predictive in vitro and in vivo methods 1 have to be taken into account. Current technologies sustain the use of scientifically valid alternative methods in order to predict local toxicity and genotoxicity, in agreement with regulatory and ethical requests. However, single-and repeated-dose systemic toxicity, toxicokinetic, sensitization, reproductive toxicity, and carcinogenicity tests are not yet replaced by nonanimal methods. 1 Scientists are being challenged to develop and to use animal replacement methods in order to better understand the biological mechanisms of diseases and to test products. These methods must be relevant to human health and be based on Integrated Approaches to Testing and Assessment (IATA), as observed by the adverse outcome pathway, 2 and even in advanced computer-modeling techniques (in silico). 3 In the cosmetic market, animal testing has been officially banned in the European community since 2013, followed by other countries, such as Norway, Israel, India, and New Zealand, 4 in the global Cosmetic Compliance Summit Report of 2015. In Brazil, significant advances have been observed in the last few years and the leading cosmetic groups are already working in agreement with this philosophy.
The Brazilian scenario of alternative methods for cosmetic product evaluation, when considering the regulatory status and the ethical standards around the globe, and the endpoints that are required for cosmetic product safety evaluation, in relation to the existing alternative methods, are reviewed and discussed here.
Alternative Methods
The European Union Reference Laboratory for alternatives to animal testing (EURL-ECVAM at the Joint Research Centre of the Institute for Health and Consumer Protection, IHCP) was formally established in 2011, in order to develop and to validate new alternative methods in the European Union. Alternative methods can be defined as procedures that completely replace the use of animals, reduce the number of animals required, or lessen the pain or discomfort suffered by them, consolidating in the concept of the 3R. 5 However, for regulatory purposes, validated alternative methods are required to undergo a chemical safety assessment, being a validation defined as being the process by which the reliability and the relevance of a particular approach, method, process, or assessment is established for a defined purpose. This definition was agreed at a CAAT/ ERGATT workshop on the principles of the validation of toxicity test procedures that were held in Amden, Switzerland, in 1990, 6 but they owed much to an excellent report on validation produced by Frazier for the Organization for Economic Co-operation and Development (OECD), 7 and to discussions that had taken place at a CAAT symposium on validation held in 1987. 8, 9 When regulatory authorities formally accept a test method that is used to provide information to meet a specific regulatory requirement, it reaches its regulatory acceptance, as observed by the Food and Drug Administration (FDA), the Environmental Protection Agency (EPA), and the OECD countries, which have recognized the alternative methods as being valuable tools for modern toxicology. The tests that agencies everywhere in the world require for cosmetics and other products are always performed in accordance with standardized methods. 10 Nevertheless, not all valid methods have regulatory acceptance, being valid methods that are applicable, defensible, fitting, proper, and well founded for a purpose, but have not yet been validated and, for instance, have not been accepted by the regulatory bodies. In spite of this, they have been proved to be useful in assessing the local tolerance of cosmetic ingredients. Basically, a sufficient amount of scientific data exists, proving their relevance and reliability, following the concept of weight of evidence. This can be defined as the process of considering the strengths and weaknesses of various pieces of information, and when reaching and supporting a conclusion concerning a property of the substance.
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The validation procedure involves a number of welldefined steps. It is important to emphasize that there must be independence between the groups that perform the distribution, the material analysis, the data analysis, and the samples that have to be coded. 12 Thus, the validation process involves the following steps:
Prevalidation: Interlaboratory study on a small scale, carried out in order to ensure that the protocol is sufficiently standardized for inclusion in a formal validation study. Phase I-Refinement: Where the Lab 1 or ''leader'' develops the method, describes the protocol, and defines the parameters. Phase II-Transfer: Where Lab 1 disseminates the protocol for Labs 2 and 3. At this stage, it takes advantage to verify the protocol transferability.
Phase III-Implementation: Where the Labs 1, 2, and 3 perform the experimental protocol and where this preliminary data is evaluated.
Validation studies can be considered as prospective or retrospective, depending upon the format that they were carried out. Basically, a prospective study involves the generation of new data, while a retrospective study reassesses the existing data. Subsequent steps must be taken to submit the method for regulatory consideration and for the possible establishment of regulations and guidelines. Incorporation of the alternative techniques into the OECD guidelines makes them officially available worldwide for toxicological testing. 10 In 2009, the International Cooperation on Alternative Methods (ICATM) was established. The United States, Canada, Japan, and the EU signed a memorandum of cooperation, with the goal of reducing the number of animals required for consumer product safety testing worldwide. The agreement yielded globally coordinated scientific recommendations, on alternative toxicity testing methods, and that this agreement should speed up their adoption in each of these countries, thus reducing the number of animals needed for product safety testing. The ICATM works in strong collaboration with the following organizations: the International Conference on Harmonization (ICH) (for the technical requirements for the registration of pharmaceuticals for human use), the OECD (which has a test guideline program that deals with chemicals), and the International Cooperation on Cosmetics Regulation. Briefly, ICATM's main goals are (1) to establish international cooperation in the critical areas of validation studies, independent peer reviews, and the development of harmonized recommendations, in order to ensure the worldwide acceptance of the alternative methods and strategies, and (2) to establish the necessary international cooperation, in order to ensure that the new alternative testing methods/strategies are adopted for regulatory use, and will provide equivalent or improved protection for people, animals, and the environment, while replacing, reducing, or refining (causing less pain and distress) animal use, wherever is scientifically feasible.
The EU chemical legislation REACH gives provisions on testing methods through Regulation (EC) 1907/2006 concerning the registration, authorization, and the restriction of chemicals. It gives a prominent role to nonanimal methods and approaches and contains an explicit cross-reference to principles laid down in Directive 86/609/EEC (now replaced by 2010/63/EU, on the protection of animals used for scientific purposes) 13 ; REACH implements the 3R and the ''last resort'' principle; it establishes a ''Regulation on Test Methods.'' REACH annexes specify information requirements and applicable test methods. REACH also promotes the use of alternative methods, in order to reduce animal testing, by obliging registrants to collect and examine existing data, before performing new tests. It has a far-reaching provision to waive testing by using nontesting approaches: grouping, read-across, QSAR, and a possibility to replace in vivo data by in vitro test results/weight of evidence assessment.
The Brazilian commitment, with a validation of alternative methods, resulted in the creation of the National Network of Alternative Methods (RENAMA) in July 2012 by the Ministry of Science, Technology and Innovation (MCTI) and in September 2012 of the Brazilian Center for the Validation of Alternative Methods (BraCVAM), a partnership between the National Institute of Health Quality Control (INCQS/Fiocruz) and the National Health Surveillance Agency (ANVISA). These were the first partnerships in Latin America to validate and to coordinate a studies substitution, a reduction, or a refinement, of the use of animals in laboratory tests.
Regulatory Aspects
The European Commission (EC) defined cosmetic products as ''any substance or mixture intended to be placed in contact with the external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and the mucous membranes of the oral cavity, with a view to exclusively or mainly cleaning them, perfuming them, changing their appearance, protecting them, keeping them in a good condition, or correcting body odors.'' 13 In Brazil, the Brazilian Health Surveillance Agency (ANVISA) use the same definition, but classifies cosmetic products into two classes, grades 1 and 2, according to the likelihood of unwanted effects due to an inappropriate use of the product, its formulation, the purpose of use, and for those areas of the body for which it is intended, together with the precautions to be observed when using it.
14 These products only accidentally enter into the blood's circulation and their chemical reactivity is not intended to interfere with biological processes. Around the globe, as a public backlash against cosmetic testing on animals increases, it is pushing the cosmetic industry to commit to ultimately eliminating the need to conduct animal testing.
The seventh amendment of the Cosmetic Directive (CD) (76/768/EC) that was entered into action in March 2013 banned all animal tests for those cosmetic products to be sold in the European Union (EU), without reducing the requirements for their safety assessment. The same provisions were contained in the Cosmetics Regulation (EU Regulation 1223/2009), which replaced the Cosmetics Directive, as of July 11, 2013. 15 The Brazilian National Council to Control Animal Experimentation (CONCEA) is the legal authority responsible for regulating the use of animals in teaching and scientific activities (Brazilian Law 11,794/2008). 16 The CONCEA aims to discipline the humanitarian and ethical use of animals, within the purpose of teaching, research, and technological development; to coin legal security in relation to the use of the animals; to legitimate the implementation of policies related to the control of animal experimentation (i.e., a policy's alternative methods); to define and to make known the penalties for infractions; and to provide transparency for society regarding the use of animals in teaching and scientific activities. Among the activities of the CONCEA, the main roles are regulation, registering, and licensing those public and private institutions that use animals in teaching and scientific activities. In addition, the CONCEA must provide a legal basis for the surveillance of those institutions and monitor the implementation of alternative methods.
The CONCEA established a procedure to introduce validated alternative methods (Normative Resolution RN17/ 14), 17 regulating the recognition of alternative methods in the use of animals used in research activities in Brazil, pausing to consider the infrastructure and the expertise available, together with acknowledging the regulator's perspective. Public or private institutions, such as universities, research centers, and industries, interested in a validation of alternative methods should be associated with the National Network of Alternative Methods (RENAMA). The CONCEA recognizes those alternative methods as validated by those centers for validation, or by international collaborative studies, as published in its official compendia. The CONCEA plenary is the only instance to recognize validated alternative methods when considering the opinion of the regulatory bodies.
In 2014, BraCVAM recommended 17 validated alternative methods published by the OECD that were accepted by the CONCEA after hearing the Brazilian regulatory agencies (RN 18, 2014) ( Table 1) . 18 So, up to the year 2019, the animals used in those tests must be completely replaced by the adopted methods.
Despite most of a Brazilian cosmetic company's aims to follow the testing and marketing procedures required, few laboratories follow good laboratory practices (GLP) with qualified facilities, forcing them to perform safety assessment tests abroad. As Brazilian regulatory bodies demand GLP, those facilities that perform toxicological tests require well-trained technicians and test providers that are able to follow the GLP requirements.
In Brazil, all regulators, such as the ANVISA and the Brazilian Institute of Environment and Renewable Natural Resources (IBAMA), must comply with Law 11.794/2008 and the CONCEA regulation. It is worthwhile to mention that, even before the CONCEA regulation, the ANVISA clearly accepts alternative methods for the safety evaluation of cosmetics, as is observed in its guidelines for the Safety Evaluation of Cosmetic Products, 19 except in case of children's products, or for the evaluation of new ingredients, where alternative methods are still unavailable. Also, in July 2015, the ANVISA Executive Board decided that, from now, all alternative methods recognized by CONCEA will be immediately accepted by ANVISA. 
ALTERNATIVE METHODS TO ANIMAL TESTING AND COSMETIC SAFETY 3 Evolution of Ethical Standards and Worldwide Regulation
The development and use of alternative methods in studies performed with laboratory animals is a longtime goal within the scientific community. Stephens et al. established a complete time line of the first 40 years of alternative approaches. 20 Table 2 summarizes this chronology, including an update with the events of the last few years.
In 1876, the first law to specifically regulate animal experimentation was enacted in Great Britain. However, the starting point for the reduction, the refinement, and the replacement (3R) program was in 1954, initiated by The Universities Federation for Animal Welfare-UFAWs, which resulted in the publication of The Principles Humane of Experimental Techniques in 1959, by Russell and Burch. 21 Little attention had been paid to the 3R until the 1980s. During the 1980s, new laws and protocols had been created and adopted in several countries, not only in recognizing the concept of Russell and Burch, but also in identifying the legal and moral obligations involved in seeking to reduce, refine, and replace, wherever possible, those procedures involving experimental animals. Several campaigns emerged in the developed countries, such as the Spira Draize campaign against cosmetic companies. In return, cosmetic companies and consumer product companies began seriously investing in the research and in the development of alternatives. National governments incorporated the alternative approach into their animal protection legislation and began funding the research and development of alternatives. Some companies started developing and marketing alternative testing, and academic centers devoted to the issue began to be established. The field of in vitro toxicology blossomed. 20 During the 1990s, government centers that were devoted to the validation and regulatory acceptance of alternative methods were established in Europe and in the United States. The World Congress on Alternatives and Animal Use in Life Sciences began, and alternative tests began to be formally approved and accepted by the regulatory agencies.
In Europe, the Cosmetic Regulation provided the regulatory framework for the phasing out of animal testing for cosmetics purposes. It established a prohibition for testing finished cosmetic products and cosmetic ingredients on animals (a testing ban); a prohibition to market them in the European Union; and a prohibition for finished cosmetic products with ingredients that were included in the cosmetic products and that had been tested on animals for cosmetics purposes (a marketing ban). This testing ban on finished cosmetic products was applied in September 2004. The testing ban on ingredients, or on a combination of ingredients, was applied in March 2009. The marketing ban for all human health effects was applied in March 2009, with the exception of repeated-dose toxicity, reproductive toxicity, and toxicokinetic. For these specific health effects, the marketing ban was applied in March 2013, irrespective of the availability of alternative nonanimal tests. 13 Norway and Israel in 2013, India in 2014, and New Zealand in 2015 had also adopted a testing and marketing ban. 4 The United States, Australia, and South Korea are also considering the possibility of prohibiting animal testing. China is projecting, first, not to oblige animal testing for hazard and safety evaluation and, second, to prohibit the importation of animaltested products. The Chinese Centre for the Validation of Alternative Methods (ChCVAM) was created. The Association of South East Asian Nations (ASEAN) is planning to end animal testing for cosmetics by December 2015. 4 Brazil has been the pioneer in Latin America in projecting to adopt practices related to animal testing. Brazilian discussions on the theme were intensified by the identification of the need for the establishment of the BraCVAM, 22,23 whose structure was proposed in 2009, 24 and was formally established in September 2012, as result of a partnership between the INCQS and the ANVISA. In parallel, the MCTI established the National Alternative Methods Network, a national network whose overall goal was to integrate the RENAMA laboratories to develop and/or use alternative methods, and was aimed at disseminating validated methods, and to develop and to validate new methods, in order to contribute to the increased analytical capacity of the country. This action has the aims to provide industrial and service capacity, overcoming technical barriers, and, in parallel, contributing to the achievement and expansion of the 3R in Brazil.
The RENAMA consists of 3 central laboratories, as represented by the INCQS, the National Institute of Metrology, Quality and Technology (INMETRO), and the National Biosciences Laboratory (LNBio), together with 21 associated laboratories. In the initial phase of the implementation of RENAMA (2012-2015), the following stood out: (1) an implementation of the electronic network site; (2) a mapping competency of the alternative methods in Brazil; (3) the development of an electronic management system based on an international computer network, in order to enable the traceability of data on a testing facility recognized by GLP (GLP++ systems and RENAMA-Flux); (4) an interaction with Agential National Sanitary Surveillance (ANVISA) to set internalization strategies of validated methods; (5) an implementation of the monocyte activation test (MAT), the opacity and permeability test of bovine corneal (BCOP) cytotoxicity test (OECD Guide 129), and a validation method for the potency evaluation of vaccines; and (6) the implementation of the Computer In Silico Simulations Center in the LNBio organization to support the academia and companies' development of drugs and cosmetic ingredients.
A relevant and original strategy of RENAMA was the implementation of interlaboratory comparisons in order to evaluate and monitor the performances of associated laboratories, and the stimulus toward GLP principles, and providing a confidence to regulators about the expertise of service providers. As the result of a link between the public laboratories, the research groups, and the government organizations, the application of alternative methods, to curtail or eliminate the use of animals for testing a product's safety and effectiveness, is gaining strength, and the research effort for such a philosophy is beginning to pay off.
The Ministry of Science, Technology and Innovation, together with the CNPq (National Counsel of Technological and Scientific Development), funded the Central Labs of RENAMA (of around 1.7 million of reais-roughly 0.85 million dollars), and nine group projects in the states of São Paulo, Bahia, Goiás, Rio de Janeiro, Santa Catarina, and the Rio Grande do Sul, were selected (1.2 million of BRL-roughly 0.6 million US$). These projects had two main focuses: to support the implementation of alternative methods in a general way and the development of an artificial American activist Henry Spira launches the Draize campaign against the rabbit-based eye irritancy test. As a result of the Draize campaign, Revlon gives a $750,000 grant to Rockefeller University to establish an alternatives research program. The New England Antivivisection Society gives $100,000 for alternatives research on tissue culture, and a second animal-welfare consortium provides $176,000 for chorio-allantoic membrane (CAM) test development.
1981
As a result of the Draize campaign, the cosmetics industry gives $1 million to the Johns Hopkins University to establish the Center for Alternatives to Animal Testing (CAAT) (Avon and Bristol-Myers Squibb were the leading donors). Swiss animal legislation specifically requires the consideration of alternatives. Zbinden and Flury-Roversi publish a critique of the LD50 Test. 1982 Colgate Palmolive provides $300,000 to investigate the CAM system. CAAT holds its first symposium.
1983
Switzerland provides 2 million Swiss francs over 2 years for alternatives research. The Food and Drug Administration (FDA) formally announces that it no longer requires data from the classical LD50 Test. Utrecht University in the Netherlands establishes research and education programs directed toward a further implementation of the 3R. 1984 FRAME receives £160,000 from the Home Office-the first UK government funding for alternatives research.
(continued)
ALTERNATIVE METHODS TO ANIMAL TESTING AND COSMETIC SAFETY The NIH Revitalization Act of 1993 directs the NIEHS to establish criteria for the validation and regulatory acceptance of alternative testing and to outline a process for regulatory review of potential alternative methods; it also directs the NIH director to establish an alternatives program and to report on its progress annually. The first World Congress on Alternatives and Animal Use in the Life Sciences: Education, Research, and Testing takes place in Baltimore.
(continued) Regarding the Brazilian marketing ban, São Paulo was the first state to adopt the testing ban in February 2014, prohibiting the use of animals in the testing of cosmetic products, in response to activist's pressure (State Law no. 15.316 published in January 2014). This law was implemented suddenly, without any public consultation, and being incoherent to Federal Legislation (Federal Law 11.794/2008). This promoted controversy. The total ban made it impossible to develop cosmetics with any new ingredients or molecules as discovered by Brazilian biodiversity that contained unknown molecules and interfered with the MCTI strategy of replacing, reducing, and improving the use of animals in testing whenever possible. Recently, a study addressed the impact of the implementation of this law in the state of São Paulo and concluded that the cosmetic industry would transfer its industrial pole to other federal states. This was in order to allow the cosmetic industry to continue to follow the federal legislation that still required animal testing, in order to ensure their quality and to reduce the risk of adverse effects in consumers. 25 In fact, the Brazilian Constitution guarantees that any federal law could not be modified by a state law, making the São Paulo State Law unconstitutional and, until it is regulated, it is not in force, prevailing Law 11.794/ 2008 and the CONCEA regulations.
From Alternative to Predictive Methods
An alternative method is a single or a combination of methods to reduce, refine, or replace animal testing, for any toxicological assessment. 12 For example, according to the Cosmetic Regulation, the different types of human health effects possibly induced by topical products are acute toxicity; skin irritation and corrosion; skin sensitization; skin absorption/penetration; UV-induced toxic effects; carcinogenicity; subacute and subchronic toxicity; genotoxicity and mutagenicity; toxicokinetic and metabolism; and reproductive and development toxicity. Table 3 presents the validated alternative methods for cosmetic product safety assessment.
Reducing animal testing presents both risks and benefits. Beyond reducing animal numbers, alternative methods also provide a better approximation, and permit to take into account the mechanisms of action. But it also presents some limitations, such as the application areas, the predictability of the obtained results, the economic impact, and the real incidence on the use of animals. Thus, we should first consider the origins of animal testing, which answer was expected, and with which criteria and limits ensued. A decisional tree might be designed to represent this predictive strategy, as can be observed in the Globally Harmonized System of Classification and Labeling of Chemicals, 9 to classify physical health and environmental hazards. A predictive strategy is a combination of multiple tools that could be in a systematic literature review, in silico (computerized), in tube (biochemical), in vitro (based on cells and tissue and culture), ex vivo (based on tissue excision), and in vivo (based on animal testing and a human clinical trial). Different models can be used depending on the questions asked (i.e., software, cellular lineage, primary cells, or reconstructed tissues).
No stand-alone test method allows for covering the complexity of the physiological processes of a whole body. 26, 27 Knowledge of the biology and physiology, the metabolism, and the cellular and tissue engineering culture is the key to establishing a predictive strategy. Several prerequisites have to be taken into account. Replacing animal testing by alternative methods reveals the challenge of combining several methods into an Integrated Testing Strategy (ITS) in order to obtain equivalent results. An IATA is an approach that integrates the existing knowledge bases on the classes of chemicals, with the results of biochemical and cellular assays, computational predictive methods, exposure studies, and other sources of information, in order to identify the requirements for targeted testing, or to develop assessment conclusions. The IATA also have the potential to further enhance an understanding of the mechanisms of action, including the consideration of relevant adverse outcome pathways that provide biological linkages between molecular initiating events, to adverse outcomes in individual organisms and populations that are the base for risk assessments. A structured approach that integrates and weighs all of the relevant existing data and informs about additional data needs to enable any regulatory decision. To this aim, the different steps that need to be analyzed are in the following order: physicochemical data; in silico data; in chemico data; in vitro data; in vivo data; information of analog chemicals; information from other relevant sources; exposure considerations; and an assessment using weight of evidence, or a predefined approach, or combination of both. First, the model has to be well defined, depending on the question and/or the endpoint that we are looking for. Does a simple model, such as a cell line, is sufficient, or is a more complex model, like a reconstructed tissue or a zebra fish, more reliable? Which conditions of culture are more adapted: static, dynamic, or microfluidic? Which gas, temperature, and humidity parameters? Which characterization: morphology, functionality, metabolic capacities, or what genetic status? The chosen method mechanistic should be based on the mode of action of the compound. The protocols have to be adapted to the physicochemical properties of the product and its mechanism, the composition of the environment, and the treatment and detection system (flow cytometer, RT-PCR, spectrophotometer, etc.). Additionally, it needs to be relevant, suitable for standardization, transferrable, and reproducible intra-and interlaboratory. According to Kandárová and Letašiová, 10 a well-validated test might consider that its performance characteristics, advantages, and limitations have been adequately determined, especially when considering some technical parameters, such as (1) sensitivity (a percentage of positive chemicals correctly identified); (2) specificity (a percentage of negative chemicals correctly identified); (3) predictivity (a percentage of predictions for a particular correct classification); (4) accuracy (an overall percentage of correct classifications); (5) reproducibility within laboratories; (6) reproducibility between laboratories; and (7) a probability for a correct classification. 10 
Concluding Remarks
The adoption of validated alternative methods (OECD guides) represents a great advancement in terms of sustainable and ethical processes for the safety evaluation of cosmetics. However, for regulatory purposes, these methods demand a GLP infrastructure, presenting a well-trained network of skilled technicians, test suppliers, and interested companies. However, these issues are still few and far between in Brazil. Cosmetic companies should be prepared for this technical challenge and might consider a change of mindset in terms of toxicological evaluation and safety assessment decisions. Furthermore, for an efficient evolution of this scenario, by the participation of the RENAMA, the BraCVAM, the CONCEA, the regulatory bodies, and other players-such as the Brazilian Society for Alternative Methods (SBMAlt)-supported by the Ministry of Science, Technology and Innovation, an integrated and strongly cooperative work must be performed for a promising future of alternative methods in Brazil.
